BC Innovations | Jul 18, 2019
Distillery Therapeutics

Small molecule NPR1 inhibitors for itch

DISEASE CATEGORY: Dermatology INDICATION: Itch NIH researchers identified 15 small molecule human NPR1 inhibitors through cell-based screening that could treat itch. The compounds inhibited NRP1, a receptor for a neuropeptide that promotes itch, with IC...
BC Week In Review | Dec 21, 2018
Company News

Astellas exercises option to acquire Potenza

Astellas Pharma Inc. (Tokyo:4503) exercised an exclusive option under an April 2015 deal and acquired Potenza Therapeutics Inc. (Cambridge, Mass.) (see "Potenza Therapeutics, Astellas Deal" ). Potenza received $164.6 million up front and is eligible...
BC Innovations | Nov 26, 2018
Distillery Techniques

Drug delivery

TECHNOLOGY: Peptides; polymers An amphiphilic dendrimer-peptide construct could be used for tumor-targeted delivery of siRNA therapies. The construct has four components: an amphiphilic dendrimer complex for loading with siRNA cargo; a peptide composed of repeating...
BC Extra | Aug 9, 2018
Preclinical News

New biological insight could lead to obesity treatment

By identifying a mechanism in dietary fat uptake, researchers from Yale University School of Medicine suggest a compound marketed for glaucoma could have therapeutic applications in obesity. The study was published Thursday in Science. Dietary...
BC Innovations | Dec 5, 2017
Distillery Therapeutics

Cancer

INDICATION: Brain cancer Mouse studies suggest inhibiting NRP1 in microglia and peripheral macrophages could help treat glioma. In a bone marrow-ablated mouse model of glioma, bone marrow transplants engineered to produce NRP1-knockout macrophages decreased tumor...
BC Innovations | Jan 12, 2017
Emerging Company Profile

Looking beyond VEGF

SemaThera Inc. launched this week to develop a recombinant SEMA3A trap to treat vascular pathologies in the large fraction of diabetic macular edema (DME) patients who don’t respond to marketed anti- VEGF therapies. Semaphorins are...
BC Innovations | Nov 12, 2015
Distillery Therapeutics

Therapeutics: Vascular endothelial growth factor receptor 1 (FLT1; VEGFR-1); neuropilin 1 (NRP1)

Ophthalmic disease Animal studies suggest local delivery of a small cyclic peptidomimetic inhibitor of FLT1 and NRP1 could help treat AMD and retinopathy of prematurity (ROP). In a monkey model of AMD, an eye drop...
BC Week In Review | Mar 30, 2015
Clinical News

Tivozanib: Phase II final data

An analysis of patients with low serum neuropilin 1 (NRP1) levels in the open-label, international Phase II BATON-CRC trial in 265 patients with previously untreated mCRC showed that first-line treatment with tivozanib plus mFOLFOX6 chemotherapy...
BC Innovations | Jul 17, 2014
Distillery Therapeutics

Indication: Ophthalmic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Ophthalmic disease Ophthalmic disease v-abl Abelson murine leukemia viral oncogene homolog 1 (ABL1); neuropilin 1 (NRP1) In vitro and mouse studies suggest ABL1 inhibitors could help...
BC Innovations | Nov 14, 2013
Distillery Therapeutics

Indication: Ophthalmic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Ophthalmic disease Diabetic retinopathy Semaphorin 3A (SEMA3A); neuropilin 1 (NRP1) Mouse studies suggest inhibiting SEMA3A could help treat diabetic retinopathy. In vitreous fluid from patients with...
Items per page:
1 - 10 of 27